Opendata, web and dolomites

MASTFAST

Rapid production of HUMAN MAST CELLS

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MASTFAST project word cloud

Explore the words cloud of the MASTFAST project. It provides you a very rough idea of what is the project "MASTFAST" about.

limit    autism    function    ground    connective    cells    hescs    airways    activated    too    validate    complement    dysregulation    medicine    yields    stem    weeks    chronic    normal    strategies    hematopoietic    made    mucosal    implicated    intestinal    cell    syndrome    wound    gene    allergies    mouse    molecules    enrichment    341096    marrow    discovery    cas9    mast    interact    produces    homogenous    differentiation    mutant    optimize    unexpected    allergic    phenotypic    cultures    ige    components    bone    goals    pathogen    few    breaking    adg    escs    rapid    release    hesc    tissue    treatments    angiogenesis    embryonic    esc    population    12    engineered    culture    functional    calls    erc    alternative    time    human    healing    personalized    anaphylaxsis    damaging    fatigue    translate    proteases    damage    drug    reporter    industry    skin    grow    hampered    dysfunction    patient    inability    treatment    mastocytoma    instead    pain    dysmotility    granules    crispr   

Project "MASTFAST" data sheet

The following table provides information about the project.

Coordinator
THE UNIVERSITY OF EDINBURGH 

Organization address
address: OLD COLLEGE, SOUTH BRIDGE
city: EDINBURGH
postcode: EH8 9YL
website: www.ed.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 148˙914 €
 EC max contribution 148˙914 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) coordinator 148˙914.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Mast cells are involved in the allergic response, anaphylaxsis, wound healing and angiogenesis. When activated via IgE, damage/pathogen-induced molecules or complement components, the granules of mast cells release proteases. Dysregulation of mast cells is implicated in allergies of the skin and airways, autism, chronic fatigue syndrome, pain, mastocytoma and intestinal dysmotility. Strategies to limit the damaging effects of mast calls are needed. However, the development of novel treatments is hampered by the inability to grow mast cells rapidly and efficiently in culture. Bone marrow cell cultures typically take 12 weeks before mast cells are available for study. Even then, there are too few cells to use for drug discovery or patient-specific treatment strategies. Embryonic stem cells (ESC) represent an alternative method for the production of mast cells. An unexpected ground-breaking discovery from our ERC AdG 341096 studies aiming to produce hematopoietic stem cells, was the development of a novel method that instead produces large numbers of mast cells in a short time. Mouse ESC engineered with a unique reporter gene that allows for cell enrichment during a multi-step culture yields a homogenous population of phenotypic and functional connective tissue and mucosal mast cells. Within only 3 weeks large numbers of mast cells are generated. To translate this method for large scale rapid production of human mast cells we will 1) characterize unique human reporter ESCs made by Crispr/CAS9 state-of-the-art method; 2) optimize human mast cell production from reporter hESCs in a multi-step differentiation culture; 3) characterize/validate the function of hESC-derived mast cells (normal and mutant); 4) interact with industry to use hESC-derived mast cells for drug-discovery and studies of mast cell differentiation and dysfunction. Long-term goals include the development of mast cell treatment strategies for personalized medicine.

 Publications

year authors and title journal last update
List of publications.
2018 Mari-Liis Kauts, Bianca De Leo, Carmen Rodríguez-Seoane, Roger Ronn, Fokion Glykofrydis, Antonio Maglitto, Polynikis Kaimakis, Margarita Basi, Helen Taylor, Lesley Forrester, Adam C. Wilkinson, Berthold Göttgens, Philippa Saunders, Elaine Dzierzak
Rapid Mast Cell Generation from Gata2 Reporter Pluripotent Stem Cells
published pages: 1009-1020, ISSN: 2213-6711, DOI: 10.1016/j.stemcr.2018.08.007
Stem Cell Reports 11/4 2020-01-23

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MASTFAST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MASTFAST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

KineTic (2020)

New Reagents for Quantifying the Routing and Kinetics of T-cell Activation

Read More  

E-DURA (2018)

Commercialization of novel soft neural interfaces

Read More  

OSIRIS (2020)

Automatic measurement of speech understanding using EEG

Read More